MVA-BN was approved by the European Medicines Agency (EMA) today for use against Mpox and smallpox in adolescents 12-17 years of age. This is of huge importance given the current Mpox outbreak has yet to be controlled and has disproportionately impacted children. Dr. Diemert and the GW VRU team are proud to have contributed critical clinical research needed to get this vaccine approved for this vital vulnerable population.
The Mpox Vaccine, MVA-BN, Receives Approval for Use in Adolescents 12 - 17 years of age
Latest News
Dr. David Diemert, the director of the George Washington University Vaccine Research Unit, weighs in on President Donald Trump's executive order pushing for revisions to how children in the US are vaccinated and what that means for the future.
The GW VRU is a site for a clinical trial to examine Pfizer's new C. diff vaccine.
This was a phase 2, randomized, open-label, non-placebo controlled trial to evaluate two partial doses o the Modified Vaccinia Ankara-Bavarian Nordin (MVA-BN) vaccine for protection against mpox.
